Heparin Effect in sepsis
Phase 3
- Conditions
- Sepsis, unspecifiedsepsis.
- Registration Number
- IRCT2015071122668N1
- Lead Sponsor
- Vice Chancellor for research of Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
inclusion criteria:
patients above 18 years old; critically ill patients with sepsis and procalcitonin above 1; patients with signed consent form
exclusion criteria:
pregnancy; lactation; platelets count under 30000; patients who need heparin for DVT treatment; patients who undergone transplantation; patients who receive other anticoagulants; patients with heparin-induced thrombocytopenia history; allergy to heparin; acute kidney failure and chronic kidney failure
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clotting time variation. Timepoint: before heparin initiation, day 2, day7. Method of measurement: time (sec) with ROTEM.;Plasminogen Activator Inhibitor-1 level. Timepoint: before heparin initiation, day 2, day7. Method of measurement: PAI-1 Kit.;Neutrophil Gelatinase-associated Lipocalin level. Timepoint: before heparin initiation, day 2, day7. Method of measurement: NGAL Kit.
- Secondary Outcome Measures
Name Time Method ICU stay. Timepoint: day of discharge from ICU. Method of measurement: number of days of staying in ICU.;Mortality. Timepoint: 28 days after admission. Method of measurement: number of expired patients in first 28 days of admission.